Compare Moderna, Inc. (MRNA) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rockwell Automation — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Rockwell Automation trades at $466.2 (market cap $51.04B). The key difference: Rockwell Automation is far larger — about 2.2× Moderna, Inc.'s market cap, and Rockwell Automation pays a 1.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | ROK | |
|---|---|---|
Market Cap | $23.60B | $51.04B |
Sector | Health | Industrials |
52-Week High | $81.80 | $495.08 |
52-Week Low | $22.36 | $328.67 |
Enterprise Value | $19.70B | $54.67B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Rockwell Automation (ROK) trades at $464.82, up 0.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 48.92% gross margin and 12.45% net margin, though valuation multiples like a 47.63 P/E appear elevated. Recent news highlights growth in industrial automation and AI infrastructure partnerships, including a contract with Aalo Atomics for nuclear reactor control systems (PRNewsWire, July 16, 2026).
Outlook is mixed: analyst consensus is a Buy with a $471.71 price target, but technical indicators suggest near-term pressure. Risks include margin compression and high debt levels, while opportunities lie in automation demand and new contracts. The stock offers a dividend yield of approximately 0.6% with consistent payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
